Publicaciones (22) Publicaciones de Francisca Iniesta Martinez

2024

  1. Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study

    Neurology and Therapy, Vol. 13, Núm. 1, pp. 153-164

2022

  1. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders

    Neurologia, Vol. 37, Núm. 3, pp. 178-183

  2. Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30)

    Multiple Sclerosis and Related Disorders, Vol. 66

2021

  1. Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis

    Stem Cell Research, Vol. 53

  2. Nonarteritic ischemic optic neuropathy: An updated review

    Revista Ecuatoriana de Neurologia, Vol. 29, Núm. 3, pp. 65-73

2020

  1. Erratum to “Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm” [Neurologia. 2020;35(6):357–362] (Neurología (2020) 35(6) (357–362), (S0213485320301389), (10.1016/j.nrl.2020.06.001))

    Neurologia

  2. Intramuscular Injection of Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis Patients: A Randomized Clinical Trial

    Frontiers in Neuroscience, Vol. 14

  3. Possible Influence of the Route of Treatment Administration on Treatment Adherence in Patients With Multiple Sclerosis

    Clinical Therapeutics, Vol. 42, Núm. 5, pp. e87-e99

  4. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules

    Multiple Sclerosis and Related Disorders, Vol. 44

  5. Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm

    Neurologia, Vol. 35, Núm. 6, pp. 357-362

2019

  1. Development and validation of a brief electronic screening test for cognitive impairment in multiple sclerosis (SCI-MS Test)

    Multiple Sclerosis and Related Disorders, Vol. 28, pp. 50-56

  2. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712

2018

  1. Production via good manufacturing practice of exofucosylated human mesenchymal stromal cells for clinical applications

    Cytotherapy, Vol. 20, Núm. 9, pp. 1110-1123

2016

  1. Breathing pattern in a phase I clinical trial of intraspinal injection of autologous bone marrow mononuclear cells in patients with amyotrophic lateral sclerosis

    Respiratory Physiology and Neurobiology, Vol. 221, pp. 54-58

  2. Spinal cord infusion of stem cells in amyotrophic lateral sclerosis: Magnetic resonance spectroscopy shows metabolite improvement in the precentral gyrus

    Cytotherapy, Vol. 18, Núm. 6, pp. 785-796

2014

  1. Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients

    Leukemia Research, Vol. 38, Núm. 10, pp. 1199-1206

2013

  1. Acute and chronic MRI changes in the spine and spinal cord after surgical stem cell grafting in patients with definite amyotrophic lateral sclerosis: Post-infusion injuries are unrelated with clinical impairment

    Magnetic Resonance Imaging, Vol. 31, Núm. 8, pp. 1298-1308

  2. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells

    Clinical Cancer Research, Vol. 19, Núm. 9, pp. 2319-2330

2012

  1. Mesenchymal dental stem cells in regenerative dentistry

    Medicina Oral, Patologia Oral y Cirugia Bucal, Vol. 17, Núm. 6

  2. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: A pilot safety study

    Stem Cells, Vol. 30, Núm. 6, pp. 1277-1285